

# Summary financial statements

For the year to 31st December 2000

	Business performance			Merger, restructuring and disposal of subsidiaries		Total	
	2000 £m	1999 £m	CER %	2000 £m	1999 £m	2000 £m	1999 £m
<b>Summary profit and loss account</b>							
<b>Sales</b>							
Retained businesses							
• Pharmaceuticals	15,429	13,618	10	–	–	15,429	13,618
• Consumer Healthcare	2,650	2,546	3	–	–	2,650	2,546
	18,079	16,164	9	–	–	18,079	16,164
• Healthcare Services	–	632		–	–	–	632
Total sales	18,079	16,796		–	–	18,079	16,796
Manufacturing, selling and administration	(10,543)	(9,501)	(9)	(555)	(443)	(11,098)	(9,944)
Research and development	(2,510)	(2,285)	(7)	(16)	–	(2,526)	(2,285)
Healthcare Services	–	(607)		–	(30)	–	(637)
<b>Trading profit</b>	<b>5,026</b>	<b>4,403</b>	<b>12</b>	<b>(571)</b>	<b>(473)</b>	<b>4,455</b>	<b>3,930</b>
Other operating income	274	413		–	–	274	413
Income from associates	209	54		(8)	(8)	201	46
Divestments	–	–		1,402	9	1,402	9
Merger transaction costs	–	–		(121)	–	(121)	–
Net interest payable	(182)	(162)		–	–	(182)	(162)
<b>Profit before taxation</b>	<b>5,327</b>	<b>4,708</b>	<b>11</b>	<b>702</b>	<b>(472)</b>	<b>6,029</b>	<b>4,236</b>
Taxation	(1,454)	(1,327)		(245)	109	(1,699)	(1,218)
Profit after taxation	3,873	3,381	12	457	(363)	4,330	3,018
Minority interests and preference share dividends	(176)	(159)		–	–	(176)	(159)
<b>Earnings</b>	<b>3,697</b>	<b>3,222</b>	<b>13</b>	<b>457</b>	<b>(363)</b>	<b>4,154</b>	<b>2,859</b>
<b>Earnings per share</b>	<b>61.0p</b>	<b>52.7p</b>	<b>14</b>			<b>68.5p</b>	<b>46.7p</b>
<b>Dividends</b>						<b>2,097</b>	<b>2,005</b>

To illustrate "Business performance", merger items and restructuring costs in 2000 and restructuring costs and disposal of subsidiaries in 1999 have been excluded and an adjusted EPS presented. Business performance growth is at constant exchange rates.

	2000 £m	1999 £m
<b>Summary balance sheet</b>		
Fixed assets	10,322	9,292
Current assets	11,268	9,482
Creditors: amounts due within one year	(9,084)	(8,448)
Net current assets	2,184	1,034
Total assets less current liabilities	12,506	10,326
Creditors: amounts due after one year	(1,894)	(2,044)
Provision for liabilities and charges	(1,657)	(1,675)
Net assets	8,955	6,607
Equity shareholders' funds	7,711	5,464
Minority interests	1,244	1,143
Capital employed	8,955	6,607

## Summary information under US GAAP

Reduction in earnings/net income under US GAAP	(9,382)	(1,946)
Increase in shareholders' funds/equity under US GAAP	37,284	1,766
Net (loss)/income	(5,228)	913
Net (loss)/income per Ordinary Share	(145.6p)	25.2p
Shareholders' equity	44,995	7,230